Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis
- 30 June 2007
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 29 (6), 1128-1145
- https://doi.org/10.1016/j.clinthera.2007.06.002
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Neutralizing anti-IFN-β antibodiesNeurology, 2005
- Interferon β-1a in MSNeurology, 2005
- Neutralizing antibodies and efficacy of interferon β-1aNeurology, 2005
- Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosisZeitschrift für Neurologie, 2005
- The clinical impact of interferon beta antibodies in relapsing-remitting MSZeitschrift für Neurologie, 2004
- Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosisThe Lancet, 2003
- Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1bNeurology, 2003
- Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing ManagementThe Neurologist, 2002
- Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosisNeurology, 1998
- Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1bNeurology, 1996